## **Case Details**

## **Case 1 (Intracranial venous sinus thrombosis)**

Patient		Daily dose Duration	Adverse reactions	
Gender	Reason for	1 tablet		
/Age	use		Clinical course and Treatment	Outcome
Female 20s	Dysmenorrhea, Acne, irregular menstruation	7 days	BMI, 17.3; Non-smoker; Family history, Grandfather Cerebral infarction; No prior medication; Nulliparity	Death
Medical History	Concomitant Disease		10 days before prescription  The patient visited hospital A for the first time. Hormone	
None	Anemia		test showed normal level.  Day of prescription YAZ was prescribed at hospital A.  Day 1 of treatment Treatment initiated(1 tablet/day).	
			Day 2 of treatment  Headache occurred.	
			Day 6 of prescription*  The patient visited an internal medicine department in Hospital B due to physical deconditioning. She	
			complained of headache, queasy, and palpitations from the morning. Blood pressure was 105/68. Electrocardiogram and blood test showed normal. Anaemia was serious. Intravenous drip was administered. She was treated with Domperidone, Rebamipide, and Biodiastase. No	
			convulsion in lower extremities. No paralysis.  Day 9 after prescription	
			The patient visited an internal medicine department in hospital B again. She had headache. Blood pressure was 103/70. No abnormal findings. Clotiazepam was	
			prescribed to be taken as needed. She was advised to visit gynecologist because of serious anaemia.  The patient visited hospital A again. She complained of	
			feeling sick. She had queasy and impaired appetite. Vital signs were normal. Urine ketone body test showed negative. She complained of headache after fluid replacement was performed, therefore, the prescriber	
			advised her to see a cerebral surgeon. (Total dose of YAZ was 7 tablets. Administration was immediately discontinued.)	
			The patient visited a cerebral surgery department in Hospital C. At the time of visiting, no obvious symptoms such as paralysis were seen. The patient made an appointment for examination and went back home. She vomited and had difficulty in walking.	
			Day 10 after prescription  Difficulty in movement occurred.	
			Day 11 after prescription  In the morning, mother of the patient found her incontinent on the bed. The patient was transferred to hospital D. CT and MRI were conducted. She was	
			immediately referred to hospital E. On the way to hospital E, level of consciousness was JSC III-300 and convulsion was observed. Deep cerebral venous sinus	
			thrombosis was diagnosed with CT findings. She was immediately admitted to hospital E on the day, and started to receive treatment with heparin.	
			Day 12 after prescription  Hydrocephalus was aggravated and respiratory failure occurred. Endotracheal intubation was performed.  Antiphospholipid antibody: (-). ANCA (Anti-Neutrophil Cytoplasmic Antibody): (-).	
			Day 13 after prescription  The Patient passed away. An autopsy was conducted on the same day. No marked traumatic injury was observed. There	
	nt drug: clotiazer		were no findings suggesting myocardial infarction or congenital anomaly.	

Concomitant drug: clotiazepam

\* Clinical course and Treatment were described with "Day after prescription" instead of "Day of treatment" because Day of treatment was unknown.

**Case 2 (Pulmonary artery embolism)** 

Patient Daily dos Duration		Adverse reactions	
Gender Reaso /Age us		Clinical course and Treatment	Outcome
Female late teen Dysmen		BMI, 22.7; Non-smoker; No Family history.  No thrombus-related factor was identified with a medical interview (no measurement of fibrinolytic or coagulation system marker ), no prior medication, nulliparity  Day 1 of treatment  YAZ was prescribed at a hospital and treatment initiated  (1 tablet/day) for dysmenorrhea and endometriosis	Death
Medical Concor History Dise		Loxoprofen sodium hydrate and Rebamipide were prescribed (7days).  Day 499 of treatment:  Last YAZ (2 sheets: 56T) was prescribed at a hospital.	
None None		Day 526 of treatment:  After going out, she came back to her lodging at around 21:00. The contact was lost.  Day 529 of treatment  A janitor, who tried to confirm the safety, detected her lying in the room (the same clothes when she went out on Day 526). YAZ (36T) was left.  Autopsy result  Estimated date of death: Day 526  Cause of death: pulmonary artery embolism (Thrombosis in pulmonary artery trunk was observed. No macroscopic thrombosis was found in lower extremities.)  Concomitant medications: None  Medical history: None  Smoking: None  No alcohol was detected.  No malformation and traumatic injury were observed.  Although she had been dead for 5 days or more, no remarkable finding was observed in blood test and Postmortem CT.	

Case 3 (Pulmonary embolism, Deep vein thrombosis)

		Daily dose Duration	Adverse reactions		
Gender	Reason for	1 tablet			
/Age	use		Clinical course and Treatment	Outcom	
Female	Dysmenorrhea	Ca. 1 year	BMI, 23.6; No Family history; Non-smoker; Para 2.	Death	
40s Medical	Concomitant	cu. 1 yeur	No thrombus-related factor and history of thrombosis were identified with a		
History	Disease		medical interview (no measurement of fibrinolytic or coagulation system marker), No prior medication.		
None	Uterine myoma		Cervical cytology: NILM (Negative for intra epithelial lesion or malignancy).		
1,0110	, , , , , , , , , , , , , , , , , , , ,		A myoma 4.5 cm in size was present. Prescriber proposed the Patient about		
			treatment of Yaz in case she has no anaemia by uterine myoma. Diclofenac		
			sodium was prescribed.		
			Day 1 of Description*		
			Day 1 of Prescription*  No anaemia was found, then Yaz was prescribed for		
			dysmenorrhea (1 tablet/day). Diclofenac sodium and		
			teprenone were prescribed.		
			Day 46 after prescription		
			3 sheets of Yaz were prescribed as no complaint was made by		
			the patient about adverse event.		
			Day 126 after prescription  3 sheets of Yaz, diclofenac sodium and teprenone were		
			prescribed.		
			Day 207 after prescription		
			The patient complained of right leg cramps, but no		
			tenderness when her leg was grasped by hand. Transvaginal		
			ultrasound was performed as follow-up examination. The		
			size of myoma was slightly increased to about 7 cm.  Prescriber informed her that it is advisable to receive a		
			treatment with surgery to improve the symptoms, but she		
			was not so keen to have it. Yaz (3 sheets), diclofenac sodium		
			and teprenone were prescribed. Solifenacin succinate was		
			prescribed for pollakiuria.		
			Day 222 after prescription Solifenacin succinate was prescribed.		
			Day 254 after prescription		
			Solifenacin succinate was prescribed.		
			Day 294 after prescription		
			No increase of myoma was seen with transvaginal ultrasound.		
			3 sheets of Yaz were prescribed. 2 or 3 weeks before the day of withdrawal		
			2 or 3 we	The patient complained pain and swelling of her right leg and	
			saw an orthopedist.		
			Day 369 after prescription (Withdrawal date)		
			Difficulty of breathing developed and the patient was transferred		
			to an emergency department.		
			Depressed level of consciousness (Japan Coma Scale: I-3), Tachypnoea and difficulty of breathing were observed. Blood		
			pressure, 94/74; HR, 126; SpO2, 100% under giving oxygen.		
			When the patient was transferred into the ambulance, kinking of		
			upper limbs, extension of lower limbs and ankylosis were		
			observed. Cardio-respiratory arrest developed in the ambulance.		
			After the ambulance reached the hospital, heart beating restarted.		
			After this, 2 times of cardiac arrest occurred and she was resuscitated each time, but consciousness did not come back.		
			Although body temperature decreased to 34 C-degrees by		
			therapeutic hypothermia for protection of brain, bleeding		
			developed remarkablely so the therapy was stopped. RCC: 7		
			units and FFP: 8 units were transfused.		
			Day 1 of withdrawal RCC: 3 units were transfused. Contrast-enhanced CT revealed		
			pulmonary embolism and deep vein thrombosis as well as pleural effusion. Treatment with heparin and warfarin was started.		
			Day 6 of withdrawal Renal failure was gradually advanced. Urine output decreased		
			was observed. Treatment with frusemide was made.		
			Day 7 of withdrawal Continuous hemodiafiltration was initiated. Drainage of bilateral		
			pleural effusion was made.		
			Day 9 of withdrawal Pupils dilated and Blood pressure rapidly increased appeared.		
			Intracranial pressure increased caused by brain ischemia were		
			considered and treatment with concentrated glycerin/fructose was made.		
			Day 16 of withdrawal The patient was in a condition which can be judged as brain death		

		without any discrepancy.  Day 19 of withdrawal Cardiac arrest and respiratory arrest were observed. Mydriasis and pupillary light reflex lost were seen. It was confirmed that the patient passed away.	
Concomitant drug: diclofenac sodium, teprenone, solifenacin succinate			

<sup>\*</sup> Clinical course and Treatment were described with "Day after prescription" instead of "Day of treatment" because Day of treatment was unknown.